Core Viewpoint - The company, Gilead Sciences-B (01672.HK), has selected its first oral glucagon-like peptide-1 receptor agonist, ASC36 oral tablets, for clinical development, with plans to submit an Investigational New Drug (IND) application to the FDA in Q2 2026 for obesity treatment [1][2] Group 1 - ASC36 oral tablets have shown an absolute oral bioavailability of 6% to 8% in non-human primate studies, utilizing Gilead's proprietary oral peptide delivery enhancement technology (POTENT) [1] - In non-human primates, ASC36 oral tablets led to an average weight reduction of up to 13.2% relative to baseline after 7 days of once-daily dosing, significantly reducing food intake [1] - In a head-to-head study using a diet-induced obesity (DIO) rat model, ASC36 demonstrated weight loss effects that were approximately 32% and 91% greater compared to eloralintide and petrelintide, respectively [1] Group 2 - The company has three key glucagon-like peptide-1 candidates: oral small molecule GLP-1, oral GLP-1 peptide, and monthly subcutaneous GLP-1 peptide, with ASC36 oral tablets being a significant GLP-1 agonist [2] - Gilead's competitive and differentiated product pipeline is supported by three proprietary technology platforms: AISBDD, Ultra-Long-Acting Platform (ULAP), and POTENT, aimed at addressing diverse treatment needs for obesity and other metabolic diseases [2]
歌礼制药-B(01672.HK)：选定口服胰淀素受体激动剂多肽ASC36进行临床开发